BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 24879309)

  • 1. The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma.
    Mitchell B; Mahalingam M
    Histol Histopathol; 2014 Dec; 29(12):1539-46. PubMed ID: 24879309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 in primary cutaneous melanoma--biomarkers of potential utility?
    Mitchell B; Leone D; Feller K; Menon S; Bondzie P; Yang S; Park HY; Mahalingam M
    Hum Pathol; 2014 Oct; 45(10):2094-100. PubMed ID: 25130395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
    McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
    Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway?
    Motlak M; Mathews M; Al-Odat OS; Pandey MK
    Cytokine; 2024 Jul; 179():156629. PubMed ID: 38704961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
    Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
    Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
    Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
    Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma.
    Monteagudo C; Ramos D; Pellín-Carcelén A; Gil R; Callaghan RC; Martín JM; Alonso V; Murgui A; Navarro L; Calabuig S; López-Guerrero JA; Jordá E; Pellín A
    Clin Exp Metastasis; 2012 Aug; 29(6):625-37. PubMed ID: 22526457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokines in the melanoma metastasis biomarkers portrait.
    Neagu M; Constantin C; Longo C
    J Immunoassay Immunochem; 2015; 36(6):559-66. PubMed ID: 25839711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression".
    Franco R; Botti G; Mascolo M; Loquercio G; Liguori G; Ilardi G; Losito S; La Mura A; Calemma R; Ierano C; Bryce J; D'Alterio C; Scala S
    Front Biosci (Elite Ed); 2010 Jan; 2(1):13-21. PubMed ID: 20036848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
    Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
    J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review).
    Liao YX; Zhou CH; Zeng H; Zuo DQ; Wang ZY; Yin F; Hua YQ; Cai ZD
    Int J Mol Med; 2013 Dec; 32(6):1239-46. PubMed ID: 24127013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
    Zhou W; Guo S; Liu M; Burow ME; Wang G
    Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
    Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
    Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.
    Bi J; Li P; Li C; He J; Wang Y; Zhang H; Fan X; Jia R; Ge S
    Tumour Biol; 2016 Mar; 37(3):4175-82. PubMed ID: 26490988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL14 antagonizes the CXCL12-CXCR4 signaling axis.
    Hara T; Tanegashima K
    Biomol Concepts; 2014 May; 5(2):167-73. PubMed ID: 25372750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.
    Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y
    Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the CXCR4/CXCL12 axis and its clinical implications in gastric cancer.
    Lee HJ; Jo DY
    Histol Histopathol; 2012 Sep; 27(9):1155-61. PubMed ID: 22806902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokine receptor CXCR4: role in gastrointestinal cancer.
    Lombardi L; Tavano F; Morelli F; Latiano TP; Di Sebastiano P; Maiello E
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):696-705. PubMed ID: 24120239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
    Zhou Y; Cao HB; Li WJ; Zhao L
    Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of the CXCR4/CXCL12 axis blocks the activation of the Wnt/β-catenin pathway in human colon cancer cells.
    Song ZY; Gao ZH; Chu JH; Han XZ; Qu XJ
    Biomed Pharmacother; 2015 Apr; 71():46-52. PubMed ID: 25960214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.